RAPT Therapeutics, Inc. ( NASDAQ: RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria October 20, 2025 8:30 AM EDT Good morning, and welcome to RAPT's conference ...

Chronic spontaneous urticaria (CSU) is more than a skin condition, it’s an often-misunderstood autoimmune disease that can ...

Celldex Therapeutics, Inc. has rallied over 70% off April 2025 lows, driven by optimism for lead candidate barzolvolimab in ...

Rapt Therapeutics said a mid-stage trial of its drug for chronic spontaneous urticaria, a skin condition that causes recurrent, spontaneous hives, showed comparable efficacy and safety to omalizumab, ...

Fall allergies impact millions of Americans. Many people mistake common hives for something different. it's called Chronic ...

Giselle Mosnaim, MD, an allergist and immunologist at Endeavor Health, discusses Rhapsido® (remibrutinib), a new FDA-approved oral therapy for chronic ...

CRMD, CELC, RANI, and RAPT are pushing aggressively to the upside on Monday. Here's what is driving these four biotech stocks ...

Health authorities warn of a severe strain of mpox spreading in parts of California in the United States. While cases remain ...

Most people have experienced hives at some point -- those itchy, raised welts that flare up in response to something like ...

The first oral BTK blocker for chronic spontaneous urticaria, Rhapsido offers a more convenient treatment option for patients who still show symptoms after antihistamine treatment.

Clade I mpox has been seen in the United States before, but only in people with recent travel abroad. The three cases in ...

The Food and Drug Administration (FDA) has approved Rhapsido ® (remibrutinib) for the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H 1 ...